
Layoffs 2025: The job cuts follow similar moves by Oracle, Microsoft, and other companies that have recently let go of…
Ozempic faces over 1,800 lawsuits in US courts, with damages possibly topping $2 billion. Patients allege the drug caused stomach…
Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose…
Novo Nordisk is planning a major India launch of its blockbuster weight-loss drug Wegovy, aiming for Rs 8,600 crore in…
Despite the promising results, further research is needed before GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists can be integrated…
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their purpose is to address…
Trump’s tariff threat: Experts have warned that additional levies will only serve to push up prices in the already costly…
The company predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.
Only one in seven People with obesity believe such medications would be helpful, with concerns about side effects and safety…
Prime Therapeutics reviewed pharmacy and medical claims data for 3,046 people with commercial health plans that cover GLP-1 drugs.
Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the…
Novo Nordisk had filed a patent infringement suit against Mylan over Ozempic in a US court.
Existing obesity drugs like Wegovy and Eli Lilly’s Zepbound are injectable. Pills require larger amounts of active ingredients, which makes…
As per the latest Indian Council of Medical Research–India Diabetes (ICMR-INDIAB) study, the prevalence of diabetes and other metabolic non-communicable…
With a focus on disease areas like Type 1 Diabetes, Type 2 Diabetes, Obesity, Hemophilia, Sickle-Cell Anemia, Cardiovascular diseases and…
The change will be effective from October 1, giving patients time to source a regulated drug.
Patients in the trial lost an average of nearly 10 percent of their total body weight after 65 weeks on…
The application for approval by Jiuyuan Gene Engineering comes amid surging demand for semaglutide that far outpaces supply globally.